Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Under CEO Gorsky Will Remain Diverse But Be More Selective

This article was originally published in The Pink Sheet Daily

Executive Summary

New CEO Alex Gorsky outlines his vision for the healthcare giant in his first quarterly sales and earnings presentation to investors. Short-term priorities include restoring OTC drug supply and building pharmaceutical sales momentum.

You may also be interested in...



Emerging Markets Earnings Roundup: Roche, Johnson & Johnson, Abbott (Part 1)

Emerging markets were a mixed picture for Big Pharma in the third quarter, with China the clear leader, but overall key markets continued to see slower growth, which many blamed on the slowdown in the West.

Big Pharma's EU Woes Continued In Second Quarter - Where’s The Bottom?

In addition to patent expiries, which affected pharma company performance globally, ongoing price cuts for drugs and increasing parallel trade continued to hurt pharma’s European performance in the second quarter, with the gloom unlikely to lift soon. What’s at stake is further pharma investment in Europe.

Xarelto Label Expansion Plans Slowed By FDA “Complete Response” On ACS Claim

The agency’s decision not to approve the Factor Xa inhibitor for treating acute coronary syndrome patients follows a negative recommendation by an FDA advisory committee, which was concerned about missing data in the pivotal ATLAS trial. FDA may be seeking more clarity on the issue of missing vital status follow-up for patients who withdrew consent in that study.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel